SCHEDULE 13G/A: Marshman Fund Trust II Discloses 10.6% Stake in Harmony Biosciences Holdings, Inc.
Beneficial Ownership Report
Marshman Fund Trust II has reported a beneficial ownership of 10.6% of Harmony Biosciences Holdings, Inc.'s common stock as of December 31, 2024.
Summary
- Marshman Fund Trust II, based in Florida, has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Harmony Biosciences Holdings, Inc.
- As of December 31, 2024, Marshman Fund Trust II beneficially owns 6,051,120 shares of Harmony Biosciences Holdings, Inc. common stock.
- This ownership represents 10.6% of the total outstanding common stock of Harmony Biosciences Holdings, Inc.
- The calculation of the percentage is based on 57,030,897 shares of common stock outstanding as of October 31, 2024, as disclosed by the Issuer in a Form 424B7 prospectus supplement.
- Marshman Fund Trust II holds sole voting power and sole dispositive power over all 6,051,120 shares.
Sentiment
Score: 7
Explanation: The filing of a Schedule 13G indicating a significant 10.6% beneficial ownership by an institutional investor like Marshman Fund Trust II is generally a positive signal, suggesting confidence in the company. While it's a passive filing and doesn't contain operational news, the substantial stake is a vote of confidence.
Positives
- A significant institutional investor, Marshman Fund Trust II, holds a substantial 10.6% stake, which can be interpreted as a vote of confidence in Harmony Biosciences Holdings, Inc.
- The investor has sole voting and dispositive power over their shares, indicating a clear and direct investment strategy.
Future Outlook
The document is a beneficial ownership report and does not contain any forward-looking statements or guidance from Harmony Biosciences Holdings, Inc. or Marshman Fund Trust II regarding future performance or strategy.
Industry Context
This filing indicates a significant passive investment by Marshman Fund Trust II in Harmony Biosciences Holdings, Inc., a pharmaceutical company. Such large institutional stakes are common in the biotech and pharmaceutical sectors, reflecting investor interest in specific drug pipelines, market positions, or growth potential. The filing itself does not provide broader industry trends but highlights continued institutional confidence in the sector.
Comparison to Industry Standards
- This document is a beneficial ownership filing and does not provide financial results or operational metrics for comparison to industry standards or specific comparable companies. It solely reports the ownership stake of Marshman Fund Trust II in Harmony Biosciences Holdings, Inc.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Marshman Fund Trust II may be viewed positively by other shareholders, potentially signaling confidence in the company's long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 10/31/2024 | Date as of which 57,030,897 shares of Common Stock were outstanding, as disclosed in the Issuer's Prospectus Supplement on Form 424B7. |
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 02/10/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Harmony Biosciences Holdings Inc, Marshman Fund Trust II, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, SEC Filing, HBM
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.